OmniComm Systems, Inc.
TrialOne Suite Selected for Phase I Clinic Automation
Fort Lauderdale, FL, June 25, 2014 –- OmniComm Systems, Inc. (OTCQB: OMCM), a leading global provider of clinical data management solutions for clinical trials, today announced that one of the world’s largest contract research organizations selected TrialOne to standardize processes, improve business intelligence, ensure regulatory compliance, and achieve overall business transformation across all of its global Phase I clinics.
TrialOne is a browser-based bedside data collection technology designed specifically to address the needs of Phase I clinics. Subject recruitment, study data capture, sample tracking, reporting, data management and integration with laboratory and medical monitoring equipment are all inherent capabilities of TrialOne that led this CRO to select TrialOne.
Furthermore, TrialOne’s import and export features that provide integration with laboratory information management systems for lab orders and results processing is another significant feature that drove the selection.
TrialOne enables the automation of clinic data collection; standardizes recruiting; facilitates the collection of study data and sample tracking; reduces discrepancies inherent in paper-based applications; and ensures compliance.
“We are now seeing a major increase in activity in the Phase I clinic automation market and this latest major win for OmniComm confirms our position as the market leader,” said Dr Kuno van der Post, senior vice president business development, OmniComm Systems. “The continued adoption of TrialOne by the industry’s largest organizations is a testament to the high quality of our new technology.”
About OmniComm Systems
OmniComm Systems is a leading strategic software solutions provider to the life sciences industry. OmniComm Systems is dedicated to helping the world’s pharmaceutical; biotechnology; contract research organizations; diagnostic and device firms; and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit www.OmniComm.com.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
OmniComm and TrialMaster are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.